For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $14.62 in the prior trading day, Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed at $14.76, up 0.96%. In other words, the price has increased by $0.96 from its previous closing price. On the day, 1.65 million shares were traded. AVDL stock price reached its highest trading level at $14.77 during the session, while it also had its lowest trading level at $14.362.
Ratios:
Our goal is to gain a better understanding of AVDL by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 243.33. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.41.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $12. On June 12, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $27.Rodman & Renshaw initiated its Buy rating on June 12, 2024, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1433160576 and an Enterprise Value of 1389657088. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.48 while its Price-to-Book (P/B) ratio in mrq is 15.75. Its current Enterprise Value per Revenue stands at 6.286 whereas that against EBITDA is 3903.531.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.59, which has changed by -0.014686227 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $16.66, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 29.00%, while the 200-Day Moving Average is calculated to be 52.47%.
Shares Statistics:
The stock has traded on average 1.37M shares per day over the past 3-months and 1231530 shares per day over the last 10 days, according to various share statistics. A total of 96.78M shares are outstanding, with a floating share count of 88.92M. Insiders hold about 8.42% of the company’s shares, while institutions hold 80.85% stake in the company. Shares short for AVDL as of 1755216000 were 10122790 with a Short Ratio of 7.38, compared to 1752537600 on 12312691. Therefore, it implies a Short% of Shares Outstanding of 10122790 and a Short% of Float of 12.1700004.
Earnings Estimates
The company has 5.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.12, with high estimates of $0.16 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.34 and $0.17 for the fiscal current year, implying an average EPS of $0.25. EPS for the following year is $0.85, with 5.0 analysts recommending between $1.21 and $0.49.
Revenue Estimates
8 analysts predict $73.62M in revenue for the current quarter. It ranges from a high estimate of $74.7M to a low estimate of $72.6M. As of the current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.02MFor the next quarter, 8 analysts are estimating revenue of $78.42M. There is a high estimate of $80.14M for the next quarter, whereas the lowest estimate is $76.58M.
A total of 8 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $274.9M, while the lowest revenue estimate was $270.21M, resulting in an average revenue estimate of $272.68M. In the same quarter a year ago, actual revenue was $169.12MBased on 8 analysts’ estimates, the company’s revenue will be $356.95M in the next fiscal year. The high estimate is $378.3M and the low estimate is $333.7M.
